Top Markets
Coin of the day
Kiromic BioPharma, Inc. Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc.

KRBP
株式のランク #35637
Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial... Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.
株価
$0.11
最終同期: 2025-05-07
時価総額
$3.62M
変化(1日)
78.86%
変化(1年)
0.00%
US
取引 Kiromic BioPharma, Inc. (KRBP)

カテゴリー

Kiromic BioPharma, Inc.(KRBP)の利益
2026 時点の利益 TTM: 0
Kiromic BioPharma, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Kiromic BioPharma, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益